共查询到17条相似文献,搜索用时 234 毫秒
1.
2.
3.
4.
5.
6.
目的了解广州市花都区不同经济社区人群超重/肥胖和血脂异常情况,为疾病防治提供科学依据。方法2012年6~7月对广州市花都区3个经济状况不同的社区1623名居民进行问卷调查加体检,了解不同经济社区人群超重/肥胖和血脂异常情况。结果 3个社区超重/肥胖患病率为29.4%,血脂异常患病率为45.4%;3个区居民血脂异常患病率比较,差异无统计学意义(P0.05),但3个区居民超重/肥胖患病率比较,差异具有统计学意义(P0.05),其中经济基础较薄弱的花东区较经济基础较好的城中村田美区患病率低(P0.017)。3个社区男性超重/肥胖患病率比较,差异无统计学意义(P0.05),但3个区女性超重/肥胖患病率比较,差异具有统计学意义(P0.05),其中花东区女性居民超重/肥胖患病率较田美区女性居民超重/肥胖患病率低(P0.017)。不同年龄段3个社区居民超重/肥胖和血脂异常患病率组内比较,差异具有统计学意义(均P0.05),45~65岁居民其患病率具有相对较高的趋势。结论本地区人群超重/肥胖和血脂异常患病率较高,其中超重/肥胖患病率经济基础较好的城中村较经济基础较薄弱农村高,3个社区居民超重/肥胖和血脂异常患病率45~65岁居民患病率趋向增高。 相似文献
7.
目的调查我国9省市35~70岁人群高尿酸血症患病率及其相关因素。方法采用整群抽样的方法,调查了15706例居民高尿酸血症患病情况并应用Logistic回归模型分析高尿酸血症的影响因素。结果高尿酸血症的患病率为12.08%(标化后11.57%),其中男性为14.59%(标化后14.84%),女性为10.21%(标化后9.21%);高尿酸血症患病率在女性人群中是随着年龄增长而升高(趋势卡方检验P<0.05),而在男性人群未见明显趋势(趋势卡方检验P>0.05)。高尿酸血症伴发疾病中以高脂血症最为常见(80.40%),其次为超重和肥胖(74.61%)、高血压(58.32%)、腹型肥胖(45.47%)、糖尿病(11.80%);多因素Logistic回归模型显示:年龄(OR=1.01,95%CI:1.01~1.02)、男性(OR=1.36,95%CI:1.21~1.53)、高甘油三酯血症(OR=4.28,95%CI:3.84~4.76)、高胆固醇血症(OR=1.19,95%CI:1.06~1.33)、高血压(OR=1.17,95%CI:1.05~1.30)、肥胖(OR=1.69,95%CI:1.52~1.88)、饮酒(OR=1.36,95%CI:1.19~1.56)与高尿酸血症显著相关。结论高甘油三酯血症、高胆固醇血症、年龄、男性、高血压、肥胖可能为高尿酸血症的危险因素;随着肥胖和代谢综合征发生率的增加以及高尿酸血症与心血病的密切关系,积极控制高尿酸血症对心血管疾病的控制有着十分重要的意义。 相似文献
8.
9.
目的探讨中青年超重和肥胖对高血压各亚型患病率的影响。方法选取2012年9月在我院进行体检的某单位职工为研究对象,分析其中具有完整身高、体重、血压测量资料和生化指标且未服用降压药物的共计300名研究对象的结果。比较中青年超重和肥胖对高血压各亚型患病率和血清同型半胱氨酸(Hcy)水平的影响。结果该单位员工的超重和肥胖率分别达到35%和10.33%,男性更高,30~49岁间是超重和肥胖的患病高峰。随着BMI水平增加,男性和女性的收缩压、舒张压均值和血Hcy水平逐渐升高,在超重和肥胖组中,血压的性别差异消失。肥胖组血Hcy的性别差异消失。该单位员工总体高血压患病率为16%,在超重和肥胖组中分别达到20%和45.16%,收缩期和舒张期联合高血压(SDH)和单纯舒张期高血压(IDH)患病率高于单纯收缩期高血压(ISH)。30~49岁的中青年人群高血压亚型以SDH和IDH为主。2/3以上的超重或肥胖合并SDH或IDH是分布在中青年人群。37.5%和42.85%的30~49岁肥胖者合并高Hcy血症。结论超重和肥胖人群中血压和同型半胱氨酸的性别差异消失,高血压亚型以SDH和IDH为主,大多数的超重或肥胖合并SDH或IDH发生在30~49岁的中青年,应重点针对这部分人群开展综合健康促进措施防治高血压和高同型半胱氨酸血症。 相似文献
10.
目的:了解重庆市某公职人群高尿酸血症的患病情况。方法对该人群2003、2008和2012年共9296人份体检资料进行回顾性分析,其中男4731人,女4565人,分析不同性别、年龄段人群高尿酸血症患病情况及体质量和性别对高尿酸血症患病率的影响。结果男、女人群高尿酸血症总患病率为16.6%、15.4%,性别间比较差异无统计学意义(P>0.05)。50~65岁人群高尿酸血症患病率男女间比较差异无统计学意义(P>0.05);小于35岁和35~49岁人群高尿酸血症患病率比较男性高于女性,差异有统计学意义(P<0.01);大于65岁人群高尿酸血症患病率比较女性高于男性,差异有统计学意义(P <0.01)。此人群高尿酸血症患病率随体质量指数升高而上升,肥胖人群高尿酸血症患病率高于超重人群;且超重和肥胖人群高尿酸血症患病率也高于体质消瘦和体质正常人群,差异有统计学意义(P<0.01)。结论该公职人群高尿酸血症患病率较高,超重、肥胖及女性年龄是高尿酸血症患病率的重要影响因素。 相似文献
11.
12.
13.
14.
目的研究成都地区中老年人群体质量指数(BMI)及腹型肥胖对糖尿病患病率及空腹血糖水平的影响。方法 2007年5月,采用随机抽样方法抽取50~80岁中老年人685人进行心血管危险因素调查,其男394人,女291人,年龄(63.3±0.2)岁。结果成都地区中老年人群的超重和肥胖所占的比例较大(约44.3%),按BMI分组(BMI<24 kg/m2;24 kg/m2≤BMI<28 kg/m2;BMI≥28 kg/m2)的糖尿病患病率分别为14.0%、18.7%及23.3%,组间差异有统计学意义(P=0.031)。男女分别按腹型肥胖标准分组(男性切点=85 cm,女性切点=80 cm),男性糖尿病患病率在非腹型肥胖及腹型肥胖组分别为17.9%及18.7%组间差异无统计学意义(P=0.849),女性糖尿病患病率分别为9.7%及18.4%,组间差异有统计学意义(P=0.034)。整个人群中,空腹血糖无随BMI增加而升高的趋势(P=0.071);女性人群中,空腹血糖随腰围的增加而升高(P=0.001);而在男性人群中无此趋势。在调整相关指标后,logistic回归分析提示BMI对糖尿病患病率独立影响,以BMI正常为参照,超重及肥胖的OR值分别为:1.412[95%CI(0.818,2.437),P=0.215]及2.200[95%CI(1.034,5.178),P=0.046]。在调整相关指标后,腹型肥胖在女性人群中对糖尿病患病率独立影响,以非腹型肥胖为参考,腹型肥胖的OR值为:1.394[95%CI(1.080,3.205),P=0.041],而在男性人群中无此关系。结论成都地区中老年人群超重及肥胖所占的比重较大,BMI可影响糖尿病患病率及空腹血糖水平;腹型肥胖能够影响女性人群糖尿病患病率及空腹血糖水平,但在男性人群中无此关系。 相似文献
15.
16.
M. CANONICO E. OGER† J. CONARD‡ G. MEYER§ H. LÉVESQUE¶ N. TRILLOT M. T. BARRELLIER†† D. WAHL‡‡ J. EMMERICH§§ P. Y. SCARABIN ON BEHALF OF THE ESTROGEN THROMBOEMBOLISM RISK STUDY GROUP 《Journal of thrombosis and haemostasis》2006,4(6):1259-1265
BACKGROUND: Oral estrogen use and elevated body mass index (BMI) increase the risk of venous thromboembolism (VTE). Recent data suggest that transdermal estrogen might be safe with respect to thrombotic risk. However, the impact of transdermal estrogen on the association between overweight (25 kg m(-2) < BMI < or = 30 kg m(-2)) or obesity (BMI >30 kg m(-2)) and VTE risk has not been investigated. METHODS: We carried a multicenter case-control study of VTE among postmenopausal women aged 45-70 years, between 1999 and 2005, in France. Case population consisted of women with a first documented idiopathic VTE. We recruited 191 hospital cases matched with 416 hospital controls and 62 outpatient cases matched with 181 community controls. RESULTS: The odds ratio (OR) for VTE was 2.5 [95% confidence interval (CI):1.7-3.7] for overweight and 3.9 (95% CI: 2.2-6.9) for obesity. Oral, not transdermal, estrogen was associated with an increased VTE risk (OR = 4.5; 95% CI: 2.6-7.7 and OR = 1.1; 95% CI: 0.7-1.7, respectively). Compared with non-users with normal weight, the combination of oral estrogen use and overweight or obesity further enhanced VTE risk (OR = 10.2; 95% CI: 3.5-30.2 and OR = 20.6; 95% CI: 4.8-88.1, respectively). However, transdermal users with increased BMI had similar risk as non-users with increased BMI (OR = 2.9; 95% CI: 1.5-5.8 and OR = 2.7; 95% CI: 1.7-4.5 respectively for overweight; OR = 5.4; 95% CI: 2.1-14.1 and OR = 4.0; 95% CI: 2.1-7.8 respectively for obesity). CONCLUSIONS: In contrast to oral estrogen, transdermal estrogen does not confer an additional risk of idiopathic VTE in women with increased BMI. The safety of transdermal estrogen on thrombotic risk has to be confirmed. 相似文献
17.
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TGs) are associated with an increased incidence of coronary heart disease (CHD). However, limited data are available about the prevalence of dyslipidemias related to LDL-C, HDL-C, and TGs among French patients treated with lipid-lowering agents. OBJECTIVE: This paper describes the prevalence of various types of dyslipidemias among patients treated with lipid-lowering agents in French general practice. METHODS: This was a cross-sectional, observational study conducted using retrospective data collection at the time of enrollment. Eligible patients were those treated pharmacologically for dyslipidemia in the Cegedim Strategic Data general practice network. Fasting lipid values and cardiovascular (CV) risk factors were gathered by investigators using an ad hoc questionnaire. European guidelines were used to define various types of dyslipidemias. Polytomous logistic regression was used to assess the associations between different dyslipidemias and diabetes mellitus, a history of CHD, and the number of CV risk factors. RESULTS: A total of 946 patients had a complete lipid profile and valid data for determining CV risk status. The mean (SD) age of these patients was 64.0 (9.9) years, and 55.7% of the patients were men. At least 1 abnormality in LDL-C, HDL-C, or TGs was present in 791 (83.6 %) of the 946 patients. The rates of elevated LDL-C, low HDL-C, and elevated TGs were 73.2%, 16.9%, and 30.3%, respectively (these groups are not mutually exclusive). Among those who did not reach the LDL-C goal, 38.7% had dyslipidemias with low HDL-C, elevated TGs, or both. Compared with having a normal lipid profile, each additional CV risk factor increased the likelihood of the following types of dyslipidemias: low HDL-C and/or elevated TGs, but normal LDL-C (odds ratio [OR], 1.36; 95% CI, 1.03-1.79); elevated LDL-C and TGs, but normal HDL-C (OR, 1.58; 95% CI, 1.24-2.02); and all 3 lipid abnormalities (OR, 1.54; 95% CI, 1.10-2.14). Patients with diabetes had a similarly increased risk of mixed dyslipidemias, whereas patients with a history of CHD did not. CONCLUSIONS: Among these patients treated with lipid-lowering agents, 38.7% had mixed dyslipidemias, including low HDL-C, elevated TGs, both low HDL-C and elevated TGs, or all 3 lipid abnormalities. Patients with a greater number of nonlipid CV risk factors or with diabetes had a significantly increased risk of mixed dyslipidemias involving elevated TGs and/or low HDL-C in addition to elevated LDL-C. 相似文献